HK Stock MarketDetailed Quotes

CANBRIDGE-B (01228)

Watchlist
  • 2.040
  • +0.050+2.51%
Trading May 6 13:54 CST
1.21BMarket Cap72.86P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

CANBRIDGE-B (01228) Income Statement

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q6)Jun 30, 2025
(FY)Dec 31, 2024
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
Turnover
-41.27%49.98M
-50.33%22.25M
-17.27%85.1M
4.05%44.79M
30.26%102.87M
23.97%43.05M
153.43%78.97M
184.84%34.73M
158.98%31.16M
527.16%12.19M
Operating income
-41.27%49.98M
-50.33%22.25M
-17.27%85.1M
4.05%44.79M
30.26%102.87M
23.97%43.05M
153.43%78.97M
184.84%34.73M
158.98%31.16M
527.16%12.19M
Cost of sales
58.90%-12.66M
55.54%-6.83M
20.43%-30.8M
6.21%-15.36M
-28.69%-38.71M
-30.36%-16.37M
-142.86%-30.08M
-134.65%-12.56M
-140.30%-12.39M
-538.78%-5.35M
Operating expenses
58.90%-12.66M
55.54%-6.83M
20.43%-30.8M
6.21%-15.36M
-28.69%-38.71M
-30.36%-16.37M
-142.86%-30.08M
-134.65%-12.56M
-140.30%-12.39M
-538.78%-5.35M
Gross profit
-31.27%37.33M
-47.62%15.42M
-15.37%54.3M
10.35%29.44M
31.23%64.16M
20.35%26.68M
160.41%48.89M
224.13%22.17M
172.99%18.78M
518.35%6.84M
Selling expenses
36.71%-47.4M
43.00%-22.67M
10.49%-74.9M
-3.77%-39.78M
3.58%-83.67M
10.07%-38.33M
13.86%-86.78M
4.78%-42.63M
-97.51%-100.75M
-172.96%-44.77M
Administrative expenses
46.01%-36.8M
53.37%-16.63M
24.12%-68.16M
25.99%-35.66M
17.52%-89.83M
13.37%-48.19M
25.16%-108.91M
-5.10%-55.63M
-87.24%-145.52M
-80.41%-52.93M
Research and development expenses
82.11%-45.05M
89.62%-17.99M
2.12%-251.76M
-21.18%-173.26M
17.34%-257.21M
9.66%-142.98M
27.24%-311.17M
42.42%-158.26M
-290.05%-427.66M
-665.90%-274.84M
Revaluation surplus
----
----
----
----
----
----
----
----
29.89%-427.98M
116.99%12.61M
-Changes in the fair value of derivative financial instruments
----
----
----
----
----
----
----
----
266.08%34.45M
985.17%34.45M
-Changes in the fair value of other assets
----
----
----
----
----
----
----
----
21.58%-462.44M
71.76%-21.85M
Impairment and provision
99.17%-729K
----
---87.99M
----
----
----
----
----
----
----
-Other impairment is provision
99.17%-729K
----
---87.99M
----
----
----
----
----
----
----
Special items of operating profit
2,082.74%109.71M
538.90%102.88M
-65.56%-5.53M
-115.38%-23.44M
82.07%-3.34M
10.69%-10.88M
-302.60%-18.64M
-216.69%-12.19M
3,934.17%9.2M
12,332.14%10.44M
Operating profit
103.93%17.05M
125.14%61.01M
-17.34%-434.04M
-13.57%-242.7M
22.39%-369.89M
13.32%-213.7M
55.62%-476.61M
28.05%-246.53M
-27.52%-1.07B
-121.62%-342.65M
Financing cost
74.02%-2.23M
61.28%-1.77M
4.07%-8.58M
-2.47%-4.57M
-30.38%-8.95M
-79.65%-4.46M
-122.90%-6.86M
-59.31%-2.48M
20.50%-3.08M
26.47%-1.56M
Earning before tax
103.35%14.82M
123.96%59.24M
-16.84%-442.62M
-13.34%-247.27M
21.64%-378.84M
12.39%-218.16M
55.11%-483.48M
27.66%-249.01M
-27.30%-1.08B
-119.62%-344.2M
After-tax profit from continuing operations
103.35%14.82M
123.96%59.24M
-16.84%-442.62M
-13.34%-247.27M
21.64%-378.84M
12.39%-218.16M
55.11%-483.48M
27.66%-249.01M
-27.30%-1.08B
-119.62%-344.2M
Earning after tax
103.35%14.82M
123.96%59.24M
-16.84%-442.62M
-13.34%-247.27M
21.64%-378.84M
12.39%-218.16M
55.11%-483.48M
27.66%-249.01M
-27.30%-1.08B
-119.62%-344.2M
Profit attributable to shareholders
103.35%14.82M
123.96%59.24M
-16.84%-442.62M
-13.34%-247.27M
21.64%-378.84M
12.39%-218.16M
55.11%-483.48M
27.66%-249.01M
-27.30%-1.08B
-119.62%-344.2M
Basic earnings per share
102.88%0.03
124.14%0.14
-16.85%-1.04
-13.73%-0.58
21.93%-0.89
13.56%-0.51
90.03%-1.14
87.39%-0.59
7.30%-11.43
79.55%-4.68
Diluted earnings per share
102.88%0.03
124.14%0.14
-16.85%-1.04
-13.73%-0.58
21.93%-0.89
13.56%-0.51
90.03%-1.14
87.39%-0.59
7.30%-11.43
79.55%-4.68
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
--
--
--
--
--
--
Unqualified Opinion
--
Unqualified Opinion
--
Auditor
--
--
National Health Accounting Firm Co., Ltd.
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
--
(FY)Dec 31, 2025(Q6)Jun 30, 2025(FY)Dec 31, 2024(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021
Turnover -41.27%49.98M-50.33%22.25M-17.27%85.1M4.05%44.79M30.26%102.87M23.97%43.05M153.43%78.97M184.84%34.73M158.98%31.16M527.16%12.19M
Operating income -41.27%49.98M-50.33%22.25M-17.27%85.1M4.05%44.79M30.26%102.87M23.97%43.05M153.43%78.97M184.84%34.73M158.98%31.16M527.16%12.19M
Cost of sales 58.90%-12.66M55.54%-6.83M20.43%-30.8M6.21%-15.36M-28.69%-38.71M-30.36%-16.37M-142.86%-30.08M-134.65%-12.56M-140.30%-12.39M-538.78%-5.35M
Operating expenses 58.90%-12.66M55.54%-6.83M20.43%-30.8M6.21%-15.36M-28.69%-38.71M-30.36%-16.37M-142.86%-30.08M-134.65%-12.56M-140.30%-12.39M-538.78%-5.35M
Gross profit -31.27%37.33M-47.62%15.42M-15.37%54.3M10.35%29.44M31.23%64.16M20.35%26.68M160.41%48.89M224.13%22.17M172.99%18.78M518.35%6.84M
Selling expenses 36.71%-47.4M43.00%-22.67M10.49%-74.9M-3.77%-39.78M3.58%-83.67M10.07%-38.33M13.86%-86.78M4.78%-42.63M-97.51%-100.75M-172.96%-44.77M
Administrative expenses 46.01%-36.8M53.37%-16.63M24.12%-68.16M25.99%-35.66M17.52%-89.83M13.37%-48.19M25.16%-108.91M-5.10%-55.63M-87.24%-145.52M-80.41%-52.93M
Research and development expenses 82.11%-45.05M89.62%-17.99M2.12%-251.76M-21.18%-173.26M17.34%-257.21M9.66%-142.98M27.24%-311.17M42.42%-158.26M-290.05%-427.66M-665.90%-274.84M
Revaluation surplus --------------------------------29.89%-427.98M116.99%12.61M
-Changes in the fair value of derivative financial instruments --------------------------------266.08%34.45M985.17%34.45M
-Changes in the fair value of other assets --------------------------------21.58%-462.44M71.76%-21.85M
Impairment and provision 99.17%-729K-------87.99M----------------------------
-Other impairment is provision 99.17%-729K-------87.99M----------------------------
Special items of operating profit 2,082.74%109.71M538.90%102.88M-65.56%-5.53M-115.38%-23.44M82.07%-3.34M10.69%-10.88M-302.60%-18.64M-216.69%-12.19M3,934.17%9.2M12,332.14%10.44M
Operating profit 103.93%17.05M125.14%61.01M-17.34%-434.04M-13.57%-242.7M22.39%-369.89M13.32%-213.7M55.62%-476.61M28.05%-246.53M-27.52%-1.07B-121.62%-342.65M
Financing cost 74.02%-2.23M61.28%-1.77M4.07%-8.58M-2.47%-4.57M-30.38%-8.95M-79.65%-4.46M-122.90%-6.86M-59.31%-2.48M20.50%-3.08M26.47%-1.56M
Earning before tax 103.35%14.82M123.96%59.24M-16.84%-442.62M-13.34%-247.27M21.64%-378.84M12.39%-218.16M55.11%-483.48M27.66%-249.01M-27.30%-1.08B-119.62%-344.2M
After-tax profit from continuing operations 103.35%14.82M123.96%59.24M-16.84%-442.62M-13.34%-247.27M21.64%-378.84M12.39%-218.16M55.11%-483.48M27.66%-249.01M-27.30%-1.08B-119.62%-344.2M
Earning after tax 103.35%14.82M123.96%59.24M-16.84%-442.62M-13.34%-247.27M21.64%-378.84M12.39%-218.16M55.11%-483.48M27.66%-249.01M-27.30%-1.08B-119.62%-344.2M
Profit attributable to shareholders 103.35%14.82M123.96%59.24M-16.84%-442.62M-13.34%-247.27M21.64%-378.84M12.39%-218.16M55.11%-483.48M27.66%-249.01M-27.30%-1.08B-119.62%-344.2M
Basic earnings per share 102.88%0.03124.14%0.14-16.85%-1.04-13.73%-0.5821.93%-0.8913.56%-0.5190.03%-1.1487.39%-0.597.30%-11.4379.55%-4.68
Diluted earnings per share 102.88%0.03124.14%0.14-16.85%-1.04-13.73%-0.5821.93%-0.8913.56%-0.5190.03%-1.1487.39%-0.597.30%-11.4379.55%-4.68
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards IASIASIASIASIASIASIASIASIASIAS
Audit Opinions ------------Unqualified Opinion--Unqualified Opinion--
Auditor ----National Health Accounting Firm Co., Ltd.--Ernst & Young--Ernst & Young--Ernst & Young--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +7.80%
Sample Name
Sample Code
 +4.80%
Sample Name
Sample Code
 +3.99%
4
CNOOC
00883
+3.40%
5
SINOPEC CORP
00386
+2.40%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +60.31%
Sample Name
Sample Code
 +51.07%
Sample Name
Sample Code
 +44.61%
4
Emdoor Information
001314
+33.28%
5
Business-intelligence Of Oriental Nations Corporation
300166
+33.12%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -